If you have been reading about DAC group and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-05-08. Numbers and descriptions here follow the published literature rather than marketing material.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
MRI requires a magnetic field that is both strong and uniform to a few parts per million across the scan volume. The field strength of the magnet is measured in teslas – and while the majority of systems operate at 1.5 T, commercial systems are available between 0.2 and 7 T. 3T MRI systems, also called 3 Tesla MRIs, have stronger magnets than 1.5 systems and are considered better for images of organs and soft tissue. Whole-body MRI systems for research applications operate in e.g. 9.4T, 10.5T, 11.7T. Even higher field whole-body MRI systems e.g. 14 T and beyond are in conceptual proposal or in engineering design. Most clinical magnets are superconducting magnets, which require liquid helium to keep them at low temperatures. Lower field strengths can be achieved with permanent magnets, which are often used in "open" MRI scanners for claustrophobic patients. Lower field strengths are also used in a portable MRI scanner approved by the FDA in 2020. Recently, MRI has been demonstrated also at ultra-low fields, i.e., in the microtesla-to-millitesla range, where sufficient signal quality is made possible by prepolarization (on the order of 10–100 mT) and by measuring the Larmor precession fields at about 100 microtesla with highly sensitive superconducting quantum interference devices (SQUIDs).
A third ZIPRA incursion attempt in July 1969 met with similarly catastrophic results. Thereafter, ZIPRA abandoned the notion of attempting to infiltrate the country with large groups of insurgents equipped only with small arms; it limited itself to more irregular forms of warfare until it could stockpile enough heavy weaponry to mount a major conventional invasion. For its part, the ZANLA leadership criticised ZIPRA's continued fixation with winning a major conventional engagement, arguing that the failed incursions demonstrated the futility of engaging the Rhodesian military in the type of pitched battles in which it held an indisputable advantage. ZIPRA's failure to obtain support from the locals was also noted, and ZANLA began implementing a long-term covert politicisation programme to cultivate civilian support throughout its future area of operations.
== Clinical significance == LOX expression is regulated by hypoxia-inducible factors (HIFs), and, hence, LOX expression is often upregulated in hypoxic breast and head and neck tumors. Patients with high LOX-expressing tumors have poor overall survival. In fact, recent research has shown overexpression of LOX as crucial to promoting tumor growth and metastasis in several cancers, including breast cancer, non-small cell lung cancer, and colorectal cancer. LOX expression was also detected in megakaryocytes, or bone marrow cells responsible for the production of platelets. Data derived from a mouse model of myelofibrosis implicated LOX in bone marrow fibrosis. In a rodent model of breast cancer, a small-molecule or antibody inhibitors of LOX abolished metastasis. LOX secreted by hypoxic breast tumor cells crosslinks collagen in the basement membrane and is essential for CD11b+ myeloid cell recruitment. CD11b+ cells in turn adhere to crosslinked collagen and produce matrix metalloproteinase-2, which cleaves collagen, enhancing the invasion of metastasizing tumor cells. In contrast, LOX inhibition prevents CD11b+ cell recruitment and metastatic growth. In cells lacking TGF-β receptors, a deficiency that is characteristic of lung cancer, lysyl oxidase is found in high concentrations. LOX immunostaining has revealed that high LOX expression is associated with high extent of carcinoma invasion in samples obtained from surgically removed lung adenocarcinomas.
In science and technology, an arbitrary unit (abbreviated arb. unit, see below) or procedure defined unit (p.d.u.) is a relative unit of measurement to show the ratio of amount of substance, intensity, or other quantities, to a predetermined reference measurement. The reference measurement is typically defined by the local laboratories or dependent on individual measurement apparatus. It is therefore impossible to compare "1 arb. unit" by one measurer and "1000 arb. unit" by another measurer without detailed prior knowledge on how the respective "arbitrary units" were defined; thus, the unit is sometimes called an unknown unit. The unit only serves to compare multiple measurements performed in similar environment, since the ratio between the measurement and the reference is a consistent and dimensionless quantity independent of what actual units are used. Units of such kind are commonly used in fields such as physiology to indicate substance concentration, and spectroscopy to express spectral intensity. When the reference measurement is precisely defined and internationally agreed upon, arbitrary units can also be a unit capable of public comparison. One example of a publicly defined arbitrary unit is the WHO International Unit.
Sources: en.wikipedia.org
Finasteride, also known as 17β-(N-tert-butylcarbamoyl)-4-aza-5α-androst-1-en-3-one, is a synthetic androstane steroid and 4-azasteroid. It is an analogue of androgen steroid hormones like testosterone and DHT. As an unconjugated steroid, finasteride is a highly lipophilic compound.
=== 20th century === Elly Agallidis (1914–2006), Greek physical chemist Nancy Allbritton, American analytical and biochemist Marianne Angermann (1904-1977), German-Spanish-New Zealand biochemist Valerie Ashby, American chemist Barbara Askins (born 1939), American chemist Kim K. Baldridge, American computational chemist Alice Ball (1892–1916), American chemist Carolyn Bertozzi (born 1966), American biochemist Cynthia Burrows, American physical organic chemist Asima Chatterjee (1917–2006), Indian organic chemist Ecaterina Ciorănescu-Nenițescu (1909–2000), Romanian chemist Astrid Cleve (1875–1968), Swedish chemist Mildred Cohn (1913–2009), American chemist Janine Cossy (born 1950), French organic chemist Maria Skłodowska-Curie (1867–1934), Polish-French physicist and chemist (discoverer of polonium and radium, pioneer in radiology); Nobel laureate in physics 1903, and in chemistry 1911 Jillian Lee Dempsey (born 1983), American chemist Vy M. Dong, American organic chemist Abigail Doyle (born 1980), American organic chemist Odile Eisenstein (born 1949), French, theoretical chemist Gertrude B. Elion (1918–1999), American biochemist (Nobel prize in Physiology or Medicine 1988 for drug development) Margaret Faul, Irish/American organic chemist Mary Peters Fieser (1909–1997), American organic chemist Marye Anne Fox (1947–2021), American physical organic chemist Rosalind Franklin (1920–1957), British physical chemist and crystallographer Helen Murray Free (1923–2021), American chemist Gunda I.
=== Pharmacokinetics === Butizide is quickly absorbed from the gut with a bioavailability of 85%. It reaches highest blood plasma concentrations after 2.5 hours. Plasma protein binding is 60 to 80%. While the substance is metabolised in the liver, 30% are excreted in unchanged from with the urine. Elimination half-life is about four hours.
== Causes == Blistering in Bart syndrome represents a form of epidermolysis bullosa caused by ultrastructural abnormalities in the anchoring fibrils. Genetic linkage of the inheritance of the disease points to the region of chromosome 3 near the collagen, type VII, alpha 1 gene (COL7A1).
On September 20, 2024, the United States Court of Appeals for the Third Circuit overturned that decision, holding that federal law did not block plaintiffs' state law claims against Merck over Fosamax. As of June 30, 2024, about 3,115 lawsuits over Fosamax were still pending against Merck in both federal and state courts in the United States.
Sources: en.wikipedia.org
Protein kinase N1 is responsible for the phosphorylation of the TNF receptor-associated factor (TRAF1) on serine 139 under specific conditions. Murine TRAF1 is also phosphorylated by the same kinase, which leads to the silencing of IKK/NF-κB activity. The elimination of phosphorylation on serine 139 can be achieved by the replacement of TRAF1 with an Alanine residue, which consequently leads to the improved recruitment of TBK1. At the serine 789 residue, FGFR1 is phosphorylated by RSK2 when the kinase is in its active form. The signaling capabilities of FGFR1 at the serine 777 site can be weakened by phosphorylation. Serine 1047 and serine 1048 have been linked to the decreased binding affinity of ubiquitin ligase c-Cbl to EFGR when they are phosphorylated. When serine 349 is phosphorylated, the binding affinity between protein complex p62 and the protein Keap1 is strengthened, which is linked to stress response. When serine 337 is phosphorylated by protein kinase A in vitro, the DNA binding efficiency of the p50 subunit of NF-κB is greatly increased. Phosphorylation of serine and threonine residues is known to crosstalk with O-GlcNAc modification of serine and threonine residues.
=== Indigenous Affairs === In the April 2019 budget, funding for the Ministry of Indigenous Affairs was cut in half. Minister Rickford released a May 9, 2019 statement saying that the Ontario Government was "committed to do everything in its authority to support the relocation" of the Kashechewan First Nation. which is located north of Fort Albany, Ontario on the James Bay coast. The community has had flooding and infrastructure problems for many years and in April 2019, had to evacuate 2,500 members by plane when a state of emergency was called again. APTN reported, in the presence of 300 community members, both the federal and provincial governments signed the Framework Agreement with Kashechewan First Nation to commit to moving the reserve. The federal Minister of Indigenous Services Seamus O'Regan said the relocation process would probably take about eight years to complete.
==== HIV/AIDS ==== In 2013, scientists have been investigating an alternative approach to treating HIV-1/AIDS, based on the creation of a disease-resistant immune system through transplantation of autologous, gene-modified (HIV-1-resistant) hematopoietic stem and progenitor cells (GM-HSPC).
The 1984 "We begin bombing in five minutes" incident is an example of Cold War dark humor. It was a personal microphone gaffe joke between Ronald Reagan, his White House staff and radio technicians that was accidentally leaked to the US populace. At the time, Reagan was well known before this incident for telling Soviet/Russian jokes in televised debates, many of which have now been uploaded to video hosting websites.
In late January, several CDC websites, pages, and datasets related to HIV and STI prevention, and LGBT and youth health became unavailable for viewing. In mid-February, around 1,300 CDC employees were laid off. In April, it was reported that among the reductions were the elimination of the Freedom of Information Act team, the Division of Violence Prevention, labs involved in testing for antibiotic resistance, and the team responsible for recalls of hazardous infant products. Additional cuts affected the technology branch of the Center for Forecasting and Outbreak Analytics, which was established during the COVID-19 pandemic. On June 25, 2025, Kennedy announced that the U.S. was stopping its donations to the Gavi vaccine alliance, until Gavi can better demonstrate vaccine safety. The United States had been providing approximately 13 percent of Gavi's budget. On August 5, 2025, Secretary Kennedy announced that he was stopping 22 vaccine projects using mRNA technology, including Covid, RSV, and bird flu. A critic of this funding halt pointed out that mRNA vaccines have the potential for faster roll-out. On December 5, 2025, it was no longer systematically recommended for newborns of mothers having never gotten Hepatitis B to get vaccinated against this infection. The memos sparked indignation among most health experts. On February 24, 2026, more than a dozen U.S.
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.